Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP)

Journal of Magnetic Resonance Imaging

Volumn 33, Issue 2, 2011, Pages 409-416

  Huppertz, Alexander ^a   Breuer, Josy ^b   Fels, Lueder M ^b   Schultze Mosgau, Marcus ^b   Sutter, Gabriele ^b   Klein, Stefan ^b   Frericks, Bernd ^a   Hamm, Bernd ^a   Wagner, Moritz ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

contrast media; drug interactions; erythromycin; gadolinium; gadoxetic acid; magnetic resonance (MR)

Indexed keywords

ERYTHROMYCIN; GADOXETIC ACID; ORGANIC ANION TRANSPORTER 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; ECHO PLANAR IMAGING; FEMALE; HUMAN; LIVER PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; CONTRAST MEDIA; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; GADOLINIUM DTPA; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; ORGANIC ANION TRANSPORTERS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79551527684     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22458     Document Type: Article

References (37)

1. Huppertz A, Balzer T, Blakeborough A, et al. European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
2. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237: 89-98.
3. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478.
4. Kim YK, Kwak HS, Kim CS, Han YM,. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009; 30: 437-443.
5. Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 2009; 30: 1042-1046.
6. Motosugi U, Ichikawa T, Sou H, et al. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI). J Magn Reson Imaging 2009; 30: 849-854.
7. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356-364.
8. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U,. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992; 183: 59-64.
9. Kato N, Yokawa T, Tamura A, Heshiki A, Ebert W, Weinmann HJ,. Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 2002; 37: 680-684.
10. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007; 35: 779-786.
11. Pascolo L, Petrovic S, Cupelli F, et al. Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles. Biochem Biophys Res Commun 2001; 282: 60-66.
12. Koelblinger C, Schima W, Weber M, et al. Gadoxate-enhanced T 1-weighted MR cholangiography: comparison of 1.5 T and 3.0 T. Rofo 2009; 181: 587-592.
13. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
14. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ,. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724.
15. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for industry: population pharmacokinetics; 1999. Available at:. Assessed October 31, 2010.
16. Locke CS,. An exact confidence interval for untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984; 12: 649-655.
17. Hagenbuch B, Meier PJ,. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-665.
18. Hagenbuch B, Meier PJ,. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003; 1609: 1-18.
19. König J, Seithel A, Gradhand U, Fromm MF,. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443.
20. Shitara Y, Sato H, Sugiyama Y,. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 2005; 45: 689-723.
21. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y,. Inhibition of trans- porter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304: 610-616.
22. Vavricka SR, van Montfoort J, Ha HR, Meier PJ, Fattinger K,. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36: 164-172.
23. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE,. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 1999; 290: 153-157.
24. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
25. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T,. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet 2004; 19: 171-179.
26. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
27. Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999; 274: 17159-17163.
28. Konig J, Cui Y, Nies AT, Keppler D,. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-23168.
29. Smith NF, Figg WD, Sparreboom A,. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005; 1: 429-445.
30. Kiss IJ, Farago E, Kiss B, Varhelyi I,. Pharmacokinetic study of rifampicin in biliary surgery. Int J Clin Pharmacol Biopharm 1978; 16: 105-109.
31. Kindla J, Fromm MF, Konig J,. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 2009; 5: 489-500.
32. Karlowsky JA, Lagace-Wiens PR, Low DE, Zhanel GG,. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009; 34: 375-379.
33. Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H,. Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 2009; 9: 61.
34. Elseviers MM, Ferech M, Vander Stichele RH, Goossens H,; ESAC Project Group. Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf 2007; 16: 115-123.
35. Segui A, Milon D, Cormier M, Lepesant G,. Erythromycin lactobionate: pharmacokinetics and uterine tissue levels. Eur J Drug Metab Pharmacokinet 1987; 12: 153-160.
36. Josefsson K, Bergan T, Magni L,. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br J Clin Pharmacol 1982; 13: 685-691.
37. Hirano M, Maeda K, Shitara Y, Sugiyama Y,. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006; 34: 1229-1236.